Subscribe to RSS Feed

International Prostate Cancer Expert Dr. David Samadi Discusses Cardiac Drug Digoxin and Its Positive Effect on Reducing Prostate Cancer Risk

NEW YORK, NY - (Marketwire - April 13, 2011) - According to a study by scientists at Johns Hopkins published in the April 3rd issue of Cancer Discover, a journal of the American Association for Cancer Research, men who used a cardiac drug called Digoxin had a 24 percent lower risk for prostate cancer. Digitalis, also called Digoxin, which is made from the foxglove plant, has been used for centuries in homeopathic medicine for congestive heart failure and heart arrhythmia. However, the drug is not proven to prevent prostate cancer development and has significant side effects, according to Dr. David Samadi, a robotic prostatectomy and prostate cancer treatment expert, as well as Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center.

The popularity of Digoxin as a heart condition medication has declined in recent years as a result of newer drugs, but it still remains a viable option for patients. Digoxin alters enzymatic pathways for sodium and potassium in heart cells. This slows the heart rate while improving pumping action, and could potentially do the same for prostate cancer. Dr. Samadi, a robotic surgery expert who is also a urologic oncologist, feels it does show promise for treatment, "However, the next step is conducting tests on the effect on prostate cancer cells."

In the study, researchers screened more than 3,100 compounds, looking for an effect on prostate cancer cells; more than half were already existing drugs. Digoxin inhibited the growth of the cells in vitro. The researchers then tested this effect on 47,884 men from 1986 to 2006. Regular Digoxin users had a 24% lower risk of prostate cancer. Those who had used the drug for more than 10 years had more of a positive effect, with a 46% reduced risk.

Researchers will need to figure out the mechanism behind the effect of the drug on prostate cancer. New drugs could possibly be created to specifically target this mechanism, or perhaps Digoxin can be altered to only focus on the prostate gland. However, said Dr. Samadi, "Digoxin has side effects, so doctors would probably not use it in men with early-stage prostate cancer. It might be better for men with more advanced cancer and fewer suitable prostate cancer treatment options."

Dr. David B. Samadi
Ph: 1-855-DRSAMADI

Back to Press Releases

Bookmark Using:
Facebook Twitter LinkedIn Email Yahoo

Share on Facebook

Call to Make an Appointment With Dr. David Samadi:


Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.

Stephen, B

I want to take a moment to thank you and your wonderful medical team for my successful surgery. In October of 2011 I was diagnosed with prostate cancer, and I immediately did a lot of research into my plan for treatment...

Jak, K

I would Like to express my gratitude for the concern and interest you have shown during my examination last month and send you my sincerest best wishes for Peace...

A. T., Peru

"Personalmente recomiendo la “Prostatectomía Radical Laparoscópica Robotica Asistida” que ofrece muchas ventajas en comparación con la cirugía abierta. Que mejor garantía si es realizada por el Dr. David B. Samadi, quien cuenta con muchos años de experiencia y el reconocimiento internacional en la aplicación de este...

Walter K., USA

I learned I had prostrate cancer in late May 2010. I am 67 years old, diabetic, and had both TURP surgery and hernia surgery in the past. Being a Jehovah's Witness I was very concerned about the blood issue. Since conventional prostrate surgery is very bloody, it was not an option.